Lantheus Holdings, Inc. has filed a Form 8-K with the Securities and Exchange Commission (SEC) regarding its ongoing merger process with Curium US Holdings LLC. This filing is significant as it sheds light on the regulatory hurdles the company faces, which could impact the timeline and conditions of the merger.
Background on Lantheus Holdings
Lantheus Holdings, Inc. is a Delaware-based company that specializes in developing diagnostic imaging agents. The company operates under the Standard Industrial Classification code for in vitro and in vivo diagnostic substances. Lantheus is known for its innovative products in the life sciences sector, particularly in the field of medical imaging.
Understanding Form 8-K
A Form 8-K is a report that publicly traded companies must file with the SEC to announce major events that shareholders should know about. This can include mergers, acquisitions, changes in management, or other significant corporate events. The filing serves to keep investors informed about important developments that may affect their investment decisions.
Details from the Filing
In the recent filing dated October 22, 2026, with Accession Number 0001193125-26-428324, Lantheus disclosed that it entered into a merger agreement with Curium US Holdings on August 3, 2026. The merger will involve Merger Sub, a wholly owned subsidiary of Curium, merging with Lantheus, with Lantheus continuing as a subsidiary of Curium.
On October 21, 2026, both Lantheus and Curium received a request for additional information from the Federal Trade Commission (FTC) regarding the merger. This request, known as a 'Second Request,' extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The waiting period will last until both companies have substantially complied with the FTC’s request, or until the FTC terminates the waiting period sooner.
The filing states, "The parties expect to promptly respond to the Second Requests and to continue to work cooperatively with the FTC in its review of the Merger." It also mentions that the completion of the merger is still anticipated in the first half of 2027, pending the expiration of the waiting period and the satisfaction of other closing conditions specified in the merger agreement.
Impact of the Filing
This filing may affect various stakeholders, including shareholders, employees, and customers of Lantheus and Curium. Shareholders will be particularly interested in how the merger progresses and any potential delays that might arise from regulatory scrutiny. Employees may also be concerned about job security and changes in corporate structure resulting from the merger.
What's Next?
The filing does not say what happens next. However, both companies will need to respond to the FTC's Second Request and continue to work with the agency to address any concerns regarding the merger. The outcome of this regulatory review will be crucial in determining the merger's timeline and ultimate success.